WHAT ARE SOME OF THE CHALLENGES ASSOCIATED WITH PHENOTYPIC ASSAYS?
Cost of imaging-based approaches is higher than much simpler biochemical assays. In the same way that in vivo studies cost more than cell-based studies, more expensive materials and increased labor associated with sample preparation, imaging and analysis contribute to the higher cost of imaging-based PDD. In some cases, an imaging-based approach may not add value compared to a much simpler and more cost-effective approach like FLIPR or ELISA. In these cases we are quick to recommend an alternative service provider that specializes in that type of assay. The other side of assay cost is value and we believe that by combining the most relevant human cells with well thought out and innovative approaches to assay design, we can provide much higher quality information about human disease than traditional high-throughput and target-based screening approaches.
We routinely work with companies from Start-ups all the way up to Top-10 Pharma so if you have other pricing concerns please contact us and we’ll be happy to discuss ways to accommodate your budget.
Phenotypic assays that use imaging, specifically automated quantitative fluorescence microscopy or high content screening (HCS), bring their own set of challenges. We’ve tried to address how we tackle these challenges but if you have other concerns please contact us.